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PPRE-CLINICAL RESEARCH
Doxycycline Attenuates Protein Aggregation
in Cardiomyocytes and Improves Survival
of a Mouse Model of Cardiac Proteinopathy
Hanqiao Zheng, MD, PHD, Mingxin Tang, MD, Qingwen Zheng, MD,
Asangi R. K. Kumarapeli, MD, PHD, Kathleen M. Horak, BS, Zongwen Tian, PHD,
Xuejun Wang, MD, PHD
Vermillion, South Dakota
Objectives The goal of this pre-clinical study was to assess the therapeutic efficacy of doxycycline (Doxy) for desmin-related
cardiomyopathy (DRC) and to elucidate the potential mechanisms involved.
Background DRC, exemplifying cardiac proteinopathy, is characterized by intrasarcoplasmic protein aggregation and cardiac insuf-
ficiency. No effective treatment for DRC is available presently. Doxy was shown to attenuate aberrant intranuclear
aggregation and toxicity of misfolded proteins in noncardiac cells and animal models of other proteinopathies.
Methods Mice and cultured neonatal rat cardiomyocytes with transgenic (TG) expression of a human DRC-linked missense
mutation R120G of B-crystallin (CryABR120G) were used for testing the effect of Doxy. Doxy was administered
via drinking water (6 mg/ml) initiated at 8 or 16 weeks of age.
Results Doxy treatment initiated at 16 weeks of age significantly delayed the premature death of CryABR120G TG mice,
with a median lifespan of 30.4 weeks (placebo group, 25 weeks; p  0.01). In another cohort of CryABR120G TG
mice, Doxy treatment initiated at 8 weeks of age significantly attenuated cardiac hypertrophy in 1 month. Fur-
ther investigation revealed that Doxy significantly reduced the abundance of CryAB-positive microscopic aggre-
gates, detergent-resistant CryAB oligomers, and total ubiquitinated proteins in CryABR120G TG hearts. In cell cul-
ture, Doxy treatment dose-dependently suppressed the formation of both microscopic protein aggregates and
detergent-resistant soluble CryABR120G oligomers and reversed the up-regulation of p62 protein induced by
adenovirus-mediated CryABR120G expression.
Conclusions Doxy suppresses CryABR120G-induced aberrant protein aggregation in cardiomyocytes and prolongs CryABR120G-based
DRCmouse survival. (J Am Coll Cardiol 2010;56:1418–26) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.075m
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besmin-related myopathy, a well-characterized example of
roteinopathy, features the presence of desmin-positive
rotein aggregates in myocytes. Genetic studies linked this
isease to mutations in desmin, B-crystallin (CryAB), and
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010, accepted January 19, 2010.yotilin genes (1). Among these mutations, missense mu-
ation R120G of CryAB (CryABR120G) is the best studied.
ransgenic (TG) overexpression of either mouse or human
ryABR120G in mouse hearts causes aberrant protein aggre-
ation and cardiomyopathy, recapitulating key features of
uman desmin-related cardiomyopathy (DRC) (2,3). Re-
ent studies show that intrasarcoplasmic amyloidosis, a
ajor type of aberrant protein aggregation in DRC and
See page 1427
ssociated cardiomyopathy, are reversible on suppression of
ryABR120G expression and, more remarkably, significantly
ttenuated by voluntary exercise (4,5). Proteasome proteo-
ytic function is severely impaired in CryABR120G TG
ouse hearts, and aberrant protein aggregation seems to be
oth responsible for and further exacerbated by proteasome
unctional insufficiency, forming a vicious cycle (1,6).
m
p
f
f
t
g
p
d
m
c
t
f
a
f
f
o
p
i
w
a
i
a
p
p
t
t
C
m
m
c
M
A
c
C
p
C
o
A
(
d
8
w
r
N
N
c
p
C

v
t
I
m
a
i
a
p
T
r
a
t
a
L
A
a
H
n
a
A
t
c
B
4
5
E
r
t
a
n
g
s
F
d
S
K
p
m
w
BM
F
t
0
1419JACC Vol. 56, No. 17, 2010 Zheng et al.
October 19, 2010:1418–26 Doxycycline Ameliorates Desmin-Related CardiomyopathyIt is believed that abnormal protein aggregation and accu-
ulation are deleterious in all proteinopathy, regardless of the
rimary cause. Notably, aberrant protein aggregation in the
orm of pre-amyloid oligomers has been observed in most
ailing human hearts, resulting from either dilated or hyper-
rophic cardiomyopathy (4). Moreover, aberrant protein aggre-
ation recently was shown to trigger autophagic activation in
ressure-overloaded hearts (7). To this end, the well-
ocumented CryABR120G DRC mice represent a useful ani-
al model for the investigation into the pathogenic role of
ardiac aberrant protein aggregation as well as for therapeutic
argeting of aberrant protein aggregation in congestive heart
ailure.
Doxycycline (Doxy) is a Food and Drug Administration-
pproved second-generation antibiotic of the tetracycline
amily. It is suitable for long-term use because of its
avorable safety profile. It was demonstrated that Doxy has
ther important pharmacologic actions besides its antibiotic
roperties. For example, Doxy has been shown to be an
nhibitor for matrix metalloproteinases (MMPs) (8). It also
as reported that Doxy inhibits the formation of amyloid
ggregates both in vitro and in vivo (9). Furthermore, some
nvestigators (9–11) have reported that Doxy attenuated
nd delayed toxicity of oculopharyngeal muscular dystrophy
ossibly by reducing aggregation and inhibiting cell death
athways. These important recent discoveries prompted us to
est whether Doxy has therapeutic value in cardiac proteinopa-
hies. Our study revealed that Doxy significantly attenuates
ryABR120G-induced aberrant protein aggregation in cardio-
yocytes and prolongs the survival of CryABR120G DRC
ice, providing compelling evidence that Doxy is a promising
andidate for a clinical trial to treat cardiac proteinopathies.
ethods
nimals. The FVB/N inbred strain stable TG mice with
ardiomyocyte-restricted overexpression of the mouse
ryABR120G were used in this study (2). Animal use and care
rotocols used in this study were approved by the Institutional
ommittee for the Use and Care of Animals of the University
f South Dakota.
dministration of Doxy and echocardiography. Doxy
Sigma-Aldrich Corp., St. Louis, Missouri) was given in
rinking water (6 mg/ml) containing 5% sucrose, starting at
or 16 weeks of age. The control group was given drinking
ater containing 5% sucrose without Doxy. Echocardiog-
aphy was performed as described (12).
eonatal rat cardiomyocyte cultures and adenovirus infection.
eonatal rat cardiomyocytes (NRCMs) were isolated and
ultured as described (6,12). Recombinant adenoviruses ex-
ressing hemagglutinin (HA)-tagged CryABR102G (Ad-HA-
ryABR120G) or recombinant adenoviruses expressing
-galactosidase (Ad--Gal) were created as described (6). The
iruses were used at a multiplicity of infection of 10 to infect
he cultured NRCMs.
f
pmmunofluorescence confocal
icroscopy and Western blot
nalyses. Sample preparation,
mmunofluorescence staining,
nd Western blot analyses were
erformed as described (6,12).
he antibodies used include the
abbit polyclonal antibodies
gainst CryAB (Stressgen, Vic-
oria, British Columbia, Can-
da), Atg5 (Novus Biologicals,
ittleton, Colorado), ubiquitin,
tg7 (Sigma-Aldrich Corp.),
nd the mouse antibodies against
A-tag (Santa Cruz Biotech-
ology, Santa Cruz, California)
nd sarcomeric a-actinin (Sigma-
ldrich Corp.), LC3 (MBL In-
ernational, Woburn, Massa-
husetts), beclin-1 (Santa Cruz
iotechnology), Alexa Fluor
88 antirabbit Ig, Alex-Fluor
68 antimouse Ig (Invitrogen,
ugene, Oregon), and horse-
adish peroxidase-conjugated an-
imouse or antirabbit secondary
ntibodies (Santa Cruz Biotech-
ology). Alexa Fluor 568 conju-
ated phalloidin (Invitrogen, Eugene, Oregon) was used to
tain F-actin.
ilter-trap assay. This assay was performed as previously
escribed (4,6).
tatistical methods. The log-rank test was used for the
aplan-Meier survival analysis. All quantitative data are
resented as mean  SD and were analyzed by 1-factor or
ultiple-factor analyses of variance using SigmaStat soft-
are version 3.0 (Systat, Point Richmond, California),
aseline Echocardiography Analyses ofic Used for Kaplan-Meier Survival AnalysisTable 1 Baseline Echocardiogr phy Analyses ofMice Used for Kaplan-Meier Survival Analysis
NTG TG-CTL TG-Doxy
n 23 18 19
Body weight (g) 26 3.7 27 4.2 27 3.6
Heart rate (beats/min) 509 55 414 39* 413 31*
LVPW-d (mm) 0.72 0.09 0.94 0.12* 0.96 0.10*
LVID-d (mm) 3.8 0.34 3.6 0.26† 3.6 0.32†
LVPW-s (mm) 1.12 0.11 1.41 0.22* 1.46 0.18*
LVID-s (mm) 2.23 0.33 1.92 0.26* 1.90 0.31*
FS (%) 41.7 4.5 47.2 4.8* 46.9 5.4*
EF (%) 73.2 5.1 79.1 4.8* 78.8 5.3*
SV (l) 46 7.6 44 6.6 42 7.4
CO (l) 23,094 4,199 18,037 3,093* 17,256 3,439*
or all parameters, there is no statistically significant difference between the TG CTL group and
he TG Doxy group immediately before Doxy treatment. Compared with NTG littermates, *p 
.01, †p  0.05.
CO  cardiac output; CTL  control; -d  end-diastole; Doxy  doxycycline; EF  ejection
Abbreviations
and Acronyms
Ad--Gal  recombinant
adenoviruses expressing
-galactosidase
Ad-HA-CryABR120G 
adenoviruses expressing
hemagglutinin-tagged
CryABR102G
CryAB  B-crystallin
CryABR120G  missense
mutation R120G of
B-crystallin
CTL  control
Doxy  doxycycline
DRC  desmin-related
cardiomyopathy
Hsp  heat shock protein
LC3  microtubule
associated protein
light chain 3
MMP  matrix
metalloproteinase
NRCM  neonatal rat
cardiomyocyte
NTG  nontransgenic
TG  transgenicraction; FS  fractional shortening; LVID  left ventricle i
osterior wall; NTG  nontransgenic; -s  end-systole; SVnternal diameter; LVPW  left ventricle
 stroke volume; TG  transgenic.
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Doxycycline Ameliorates Desmin-Related Cardiomyopathy October 19, 2010:1418–26here applicable. The Holm-Sidak test was used for post-
oc pairwise comparisons. A p value 0.05 was considered
tatistically significant.
esults
oxy treatment significantly prolongs survival of mice
ith CryABR120G DRC. CryABR120G TG mice (line 134)
evelop concentric cardiac hypertrophy and diastolic mal-
unction at 3 months, display overt congestive heart failure
etween 5 and 6 months, and die shortly afterward (2).
ecause of the expedited course of disease progression in
his TG line, we used it to perform a Kaplan-Meier survival
nalysis on chronic Doxy treatment.
A cohort of 37 CryABR120G TG mice was divided
andomly into 2 groups: the Doxy (TG Doxy group; 19
ice) and the placebo (TG control [CTL] group; 18 mice)
roups. A parallel cohort of nontransgenic (NTG) litter-
ates was treated similarly to detect any potential adverse
ffects of Doxy or placebo on normal animals. Echocar-
Figure 1
Kaplan-Meier Survival Curves of
Missense Mutation R120G of B-Crystallin
(CryABR120G) TG Mice Treated With Doxy
Treatment of line 134 littermate CryABR120G transgenic (TG) and nontransgenic
(NTG) mice with doxycycline (Doxy) or vehicle control (CTL) was initiated at 16
weeks of age. No premature death was observed for Doxy- or CTL-treated NTG
mice (data not shown). The lifespan of CryABR120G TG mice was prolonged sig-
nificantly by Doxy treatment (p  0.01).
Echocardiography Assessments After 4 WeeksTable 2 Echocardiography Assessments Aft
Parameters NTG CTL
Heart rate (beats/min) 479 61
LVPW-d (mm) 0.74 0.07
LVID-d (mm) 3.78 0.15
LVPW-s (mm) 1.15 0.11
LVID-s (mm) 2.25 0.11
FS (%) 40.37 1.80 3
EF (%) 71.82 2.13 6
Treatment with Doxy or vehicle was initiated at 8 weeks of age. n  6
Compared with the TG CTL group, ‡p  0.01, §p  0.05.
Abbreviations as in Table 1.iography was performed the day before the initiation of
reatment. The treatment was initiated at 16 weeks of age
hen concentric cardiac hypertrophy and significantly de-
reased cardiac output were evident (Table 1). Mice of the
G CTL group showed a median lifespan of 25 weeks,
imilar to what was observed previously in the untreated TG
ice (2). However, the premature death was significantly
elayed in the TG Doxy group, with 60% of them still alive
y the time all TG CTL mice had died. Their median
ifespan was 30.4 weeks, 20.16% longer than that of the TG
TL group (p  0.01) (Fig. 1).
The treatment to the NTG cohort was terminated when
ll mice in the TG cohort died. No difference in animal
Figure 2 Doxy Reduces Cardiac Hypertrophy
in CryABR120G TG Mice
Initiated at 8 weeks of age, a cohort of line 134 TG and NTG mice were
treated with Doxy or CTL for 4 weeks and were used for gravimetric analyses.
Body weight (BW), heart weight (HW), and ventricular weight (VW) are shown in A.
The HW to tibial length ratio (HW/T) and the VW to tibial length ratio are pre-
sented in B. Shown are mean  SD. *p  0.05 versus the NTG CTL group.
#p  0.05 versus the TG CTL group. Abbreviations as in Figure 1.
xy Treatmenteeks of Doxy Treatment
oxy TG CTL TG Doxy
57 460 31 440 36
0.14 0.93 0.05* 0.82 0.06†‡
0.18 3.59 0.19† 3.52 0.23†
0.20 1.62 0.19* 1.36 0.14†§
0.14 1.75 0.31* 1.79 0.30†
2.59 51.37 6.73* 49.33 5.98*
3.19 82.87 6.22* 81.18 5.70*
ch group. Compared with the NTG CTL group, *p  0.01, †p  0.05.of Doer 4 W
NTG D
496
0.69
3.73
1.02
2.34
7.41
8.18
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October 19, 2010:1418–26 Doxycycline Ameliorates Desmin-Related Cardiomyopathyeath was observed between the Doxy- and placebo-treated
TG mice (data not shown).
oxy treatment attenuates cardiac hypertrophy in DRC
ice. To evaluate the effects of Doxy on cardiac hypertro-
hy and left ventricular function in DRC mice at an earlier
ime, another cohort of NTG and TGmice was subjected to
weeks of Doxy treatment starting at 8 weeks of age.
revious characterization of this mouse line revealed that
ardiac hypertrophy started between 1 and 3 months of age
nd the down-regulation of -myosin heavy chain and
ryABR120G expression was observed at 6 months (2).
ence, choosing the period between 2 and 3 months avoids
he potential impact from the down-regulation of TG
xpression. At 4 weeks after Doxy treatment, echocardiog-
aphy assessments revealed significantly increased thickness
n the left ventricle posterior wall at the end of both diastole
nd systole in the TG CTL mice, but the increases were
revented or were attenuated significantly in the TG Doxy
roup (Table 2). These indicate that a 4-week Doxy
reatment is sufficient to suppress cardiac hypertrophy. The
ncrease in ventricular wall thickness in CryABR120G TG
Figure 3 Doxy Reduces CryAB-Immunopositive Aggregates in C
Line 708 CryABR120G TG and NTG mice were treated with Doxy or CTL for 2 month
was immunostained for CryAB (green) and -actinin (red). Scale bar  30 m. AbTL mice was accompanied by decreased internal diameter
t end-diastole and -systole and elevated ejection fraction
nd fractional shortening. Doxy treatment did not signifi-
antly alter ejection fraction, fractional shortening, or the
nd-diastolic left ventricle internal diameter in the TG mice
Table 2). The changes in cardiac mass assessed by echo-
ardiography were confirmed by gravimetric measurements
t terminal experiments. The heart weight-to-tibial length
atio and the ventricular weight-to-tibial length ratio were
ignificantly lower in the TG Doxy group than in the TG
TL group (Fig. 2).
oxy treatment reduces aberrant protein aggregation in
RC mouse hearts. Because protein aggregation is an
mportant pathogenic process in DRC and Doxy has been
hown to suppress intranuclear protein aggregation in non-
yocytes, we further tested whether Doxy’s protection
gainst DRC was associated with any effect on aberrant
rotein aggregation in the heart.
Compared with the TG CTL group, TG Doxy hearts
howed substantially less CryAB-positive protein aggregates
y immunofluorescence confocal microscopy (Fig. 3), sig-
R120G TG Hearts
ting at 8 weeks of age. Paraformaldehyde perfusion-fixed ventricular myocardium
tions as in Figure 1.ryAB
s, star
brevia
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Doxycycline Ameliorates Desmin-Related Cardiomyopathy October 19, 2010:1418–26ificantly less sodium dodecyl sulfate (SDS)-resistant
ryAB oligomers by filter-trap assays (Fig. 4B), and mark-
dly less ubiquitinated proteins (Fig. 4C). Doxy treatment
id not change total CryAB protein levels (Fig. 4A).
oxy dose-dependently inhibits aberrant protein aggre-
ation induced by CryABR120G in cultured NRCMs. To
etermine whether Doxy-induced suppression of aberrant
rotein aggregation in the heart is cardiomyocyte-
utonomous, we further tested the effect of Doxy on
ryABR120G-induced aberrant protein aggregation in cul-
ured NRCMs. One day after the Ad-HA-CryABR120G
nfection, different doses (0.5 to 10 mM) of Doxy were
dministered daily to the culture media, and the cells were
ollected at 3 or 11 days after treatment. As revealed
reviously (4,6,13), CryAB-positive protein aggregates were
ormed in the cytoplasm of cardiomyocytes infected by
d-HA-CryABR120G, but not by Ad--Gal. The extent of
he aggregates was reduced markedly by Doxy treatment
Fig. 5). Western blot analyses showed that Doxy treat-
ents did not alter the HA-CryABR120G protein level
iscernibly in either the soluble or the insoluble fractions
Fig. 6A), but the filter-trap assays revealed that the
DS-resistant oligomeric forms of HA-CryABR120G sig-
ificantly reduced by Doxy in a dose-dependent manner
Figs. 6B and 6C), indicating inhibition of aberrant protein
ggregation by Doxy. Moreover, this inhibitory effect seems
o be more pronounced at 11 days than at 3 days.
Figure 4 Doxy Inhibits CryABR120G-Induced Protein Aggregation
The total and the soluble fractions of myocardial proteins were extracted from mic
myocardial proteins were subjected to sodium dodecyl sulfate polyacrylamide gel e
oligomeric CryAB in myocardial proteins was measured by the filter-trap assay. A re
shown. (C) Quantitative Western blot analyses of ubiquitinated proteins in the tota
densitometry data from 4 repeats (lower panel) are shown. *p  0.05 versus NTG
3-phosphate dehydrogenase; other abbreviations as in Figure 1.To determine the potential mechanism of the inhibi-
ion of protein aggregation by Doxy, we examined the
rotein expression of heat shock protein 25 (Hsp25) and
62/SQSTM1. Hsps play a critical role in preventing
rotein aggregation (13,14). p62 was shown to promote the
ormation of ubiquitinated protein inclusion bodies (15,16).
s shown in Figures 6D and 6E, p62 in both the soluble
nd the insoluble fractions and Hsp25 in the insoluble
raction were significantly up-regulated by CryABR120G
xpression, and the up-regulation of p62 but not Hsp25 was
ignificantly less in Doxy-treated cells versus vehicle-treated
ells.
ctivation of autophagy in DRC hearts is not enhanced
y Doxy. Autophagy plays an important role in protein
uality control (17). Autophagic activation was shown to
rotect against DRC in mice (18). Hence, we examined the
onversion of the native form of microtubule-associated
rotein light chain 3 (LC3-I) to the lipidated form of LC3
LC3-II) (a commonly used marker of autophagic activa-
ion) and several other autophagy-related proteins (19). The
rotein level of LC3-II, the LC3-II-to-LC3-I ratio, and a
leaved form of Atg5 (autophagy-related gene 5) in TG
TL hearts were significantly greater than those in the
TG CTL group, but no statistically significant difference
n these parameters was detected between TG CTL and
G Doxy groups (Figs. 7A and 7B) (data not shown). In
ultured NRCMs overexpressing HA-CryABR120G, Doxy at 1
ouse Hearts
e same cohort, and treatment was as described in Figure 3. (A) Total ventricular
phoresis, and CryAB levels were analyzed by Western blots. (B) SDS-resistant
ntative image (upper panel) and the densitometry data (bottom panel) are
cardial protein extract. A representative image (upper panel) and a summary of
. #p  0.05 versus TG CTL mice. AU  arbitrary unit; GAPDH  glyceraldehydein M
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October 19, 2010:1418–26 Doxycycline Ameliorates Desmin-Related Cardiomyopathynd 5 mM, but not 0.5 mM, significantly reduced LC3-II
rotein levels, but did not alter the LC3-II-to-LC3-I ratio.
oxy treatment did not change Atg7 and beclin1 protein
xpression (Figs. 7C and 7D). These results indicate that
utophagy is activated in the TG heart, but that Doxy-elicited
ardioprotection is independent of autophagy.
Collectively, our in vivo and in vitro experiments dem-
nstrate that Doxy can effectively inhibit aberrant protein
ggregation induced by CryABR120G, which likely contrib-
tes to its protection against DRC.
iscussion
espite recent advances in understanding the genetic basis
f DRC (1,3), no effective therapy is available to treat this
evastating disease. Using both cell culture and a DRC
ouse model, the present study revealed for the first time
hat Doxy can inhibit aberrant protein aggregation in
ardiomyocytes, can attenuate significantly a DRC-linked
isfolded protein-induced adverse cardiac remodeling, and
ffectively can prolong the lifespan of a well-documented
Figure 5 Fluorescent Confocal Micrographs of Immunostained
Neonatal rat cardiomyocytes (NRCMs) were infected with recombinant adenoviruse
tagged CryABR102G (Ad-HA-CryABR120G) for 24 h, followed by the addition of various
fixed and immunostained for HA-CryABR120G (green). F-actin was stained by phallo
m. Abbreviations as in Figure 1.G mouse model of DRC. These results provide compel- aing evidence that Doxy is a promising drug candidate to
reat DRC.
The dosage and route chosen here for Doxy administra-
ion were previously proven effective in treating a mouse
odel of oculopharyngeal muscular dystrophy (10). It
hould be noted that Doxy concentration used in the
rinking water (6 mg/ml) for this study was 6-fold higher
han what is used commonly to manipulate transgene
xpression in the tetracycline-inducible transgenic system.
e tested only Doxy here, but other tetracycline derivatives,
specially those with better tissue permeability (e.g., mino-
ycline), could be as effective or even more effective, as
emonstrated in neural proteinopathies (20).
Notably, Doxy treatment in our survival study was initi-
ted at a relatively late stage when DRC pathologic features
nd clinical signs are readily detectable (Table 1). The
ationale behind this experimental design is to maximize its
linical relevance. It remains to be tested, but it is very likely
hat the survival improvement by Doxy would be much
reater should the treatment be started earlier. Supporting
his prediction, we have observed that a significant attenu-
s Overexpressing CryABR120G
essing -galactosidase (Ad--Gal) or adenoviruses expressing hemagglutinin-
ntrations of Doxy as indicated. After 11 days of Doxy treatment, the cells were
d) and nuclei with 4=,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar  50NRCM
s expr
conce
idin (retion of cardiac hypertrophy without deteriorating cardiac
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Doxycycline Ameliorates Desmin-Related Cardiomyopathy October 19, 2010:1418–26unction was detected 1 month after Doxy treatment was
nitiated at 8 weeks of age (Fig. 2, Table 2), 8 weeks earlier
han the starting point of the survival study.
The mechanisms underlying Doxy’s beneficial effects on
RC are potentially quite complex because of Doxy’s
ersatile pharmacologic actions. Besides its antimicrobial
ction, Doxy is also known to inhibit MMPs. By breaking
own the extracellular matrix, MMPs play important roles
n tissue remodeling, cell migration, angiogenesis, and
nterstitial remodeling (21). Hence, Doxy’s MMP inhibi-
ion property is believed to contribute to a wide range of its
iological effects. Timed administration of Doxy seems to
rotect cardiac function by modulating post–myocardial
nfarction remodeling (22–25). We cannot rule out the
ossibility that Doxy’s MMP inhibition property may con-
ribute to its beneficial effects on DRC, but 2 lines of
vidence stand against this possibility. First, previous char-
cterization showed no significant interstitial fibrosis in the
eart of the DRC mice used here (2). Second, compared
ith NTG, myocardial activities of MMPs were not increased
n TGmice (data not shown). Notably, it was reported recently
hat Doxy mitigated cardiac remodeling without significantly
Figure 6 Doxy Dose-Dependently Inhibits CryABR120G-Induced P
Cultured NRCMs were infected with Ad-HA-CryABR120G or Ad--Gal for 24 h before D
and the insoluble (Ins) fractions of proteins were extracted from NRCMs and subje
endogenous CryAB. (B) Representative images of the filter-trap assays for SDS-res
using antihemagglutinin antibodies. (C) Changes in the oligomers detected in 4 re
analyses of Hsp25 and p62 in cells that underwent 11 days of Doxy treatment. **
untreated HA-CryABR120G-expressing cells. Abbreviations as in Figures 1, 4, and 5.ffecting myocardial MMP activities (26). pMisfolded proteins, when failed to be repaired, are escorted
y the chaperones to degradation by the ubiquitin–proteasome
ystem (1). When chaperones and/or the ubiquitin–
roteasome system are overwhelmed, misfolded proteins
ndergo aberrant aggregation, which produces initially sol-
ble oligomers. If not removed in time, the oligomers will
use to form large insoluble aggregates. The soluble oli-
omers generally are believed to be toxic, whereas the
nsoluble aggregates perhaps are not (1). Cardiac toxicity of
berrant protein aggregation was demonstrated directly by
he sufficiency of expressing a mutant prion protein or
olyglutamine preamyloid oligomers in cardiomyocytes to
nduce heart failure in mice (27,28). In the present study, we
bserved that not only insoluble aggregates (Figs. 3 and 5),
ut also oligomeric CryABR120G (Figs. 4 and 6), were
ecreased significantly by Doxy treatment in vivo and in
itro. These data suggest that Doxy may act as a pharma-
ologic chaperone that prevents CryABR120G from inducing
berrant oligomerization of endogenous and TG CryAB,
llowing the formation of normal CryAB polymers that can
xert the normal chaperoning function. Indeed, both tetra-
ycline and Doxy have been shown to interact with prion
n Aggregation in Cultured NRCMs
eatment initiation. (A) Three or 11 days after Doxy treatment, the soluble (Sol)
o Western blot analysis for CryAB. HA-CryABR120G (arrows) runs slower than
HA-CryABR120G oligomers in cells at 3 (a) or 11 (b) days of Doxy treatments
*p  0.05. **p  0.01 versus the 0 M Doxy group. (D and E) Western blot
.01 versus all HA-CryABR120G groups. #p  0.05. ##p  0.01 versus Doxy-rotei
oxy tr
cted t
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peats.
p  0roteins and to reduce in vitro prion protein aggregation
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October 19, 2010:1418–26 Doxycycline Ameliorates Desmin-Related Cardiomyopathynd in vivo infectivity (29). Supporting this notion, the same
xtent of CryABR120G protein overexpression, in the pres-
nce of Doxy, caused significantly less up-regulation of p62
Fig. 6) and less accumulation of ubiquitinated proteins
Fig. 4C). Our data suggest that Doxy’s inhibition of
berrant protein aggregation of misfolded CryABR120G may
ontribute to its protection against DRC.
Consistent with its presence in the protein aggregates-
ssociated desminopathy (30), p62 was up-regulated signif-
cantly in both the soluble and insoluble fractions of
ultured cardiomyocytes overexpressing CryABR120G. Inter-
stingly, the increases in p62 protein levels were attenuated
ignificantly by Doxy (Figs. 6D and 6E). p62 is known to
nteract with both ubiquitinated proteins in the aggregates
nd autophagosomes and target protein aggregates for
elective autophagic degradation (31). p62 also mediates the
ormation of ubiquitin-positive inclusion bodies in hepato-
ytes and neurons when autophagy is impaired, with varying
onsequences (16). The role of p62 up-regulation on aber-
ant protein aggregation in cardiomyocytes has not been
efined, but our results indicate that attenuation of p62
p-regulation likely is beneficial to the heart and may be an
nderlying mechanism of Doxy. Consistent with this pos-
ulate, the down-regulation of p62 by Doxy treatment did
Figure 7 Western Blot Analyses for Autophagy-Related Protein
(A and B) Total myocardial proteins from mice of the same cohort and treatment
A. The open arrow marks a short (or cleaved) form of autophagy-related gene 5 (A
immunoblots are summarized in B. (C and D) Cultured NRCMs were treated with D
for the immunoblots. Representative images are shown in C. The red arrow marks
*p  0.05 versus the blue bar and red bar groups; n  4 biological repeats. Abbrot seem to be caused by autophagic activation, because hoxy did not enhance autophagic activation in either the
G heart or in NRCMs expressing CryABR120G (Fig. 7).
It was reported in a TG mouse model of human
ryABR120G that stress-inducible Hsp’s were up-regulated
ifferentially in DRC hearts, with a major increase in Hsp25
xpression associated with progression to heart failure and
ncreased mortality (3). However, Hsp’s such as Hsp22,
sp70, and HspB8 disrupt oligomer formation induced
y CryABR120G under certain conditions (13,14). In both
ryABR120G TG mouse hearts (data not shown) and
ryABR120G expressing cultured cardiomyocytes, we ob-
erved a significant Hsp25 up-regulation, but Doxy treat-
ent failed to alter it (Figs. 6D and 6E). Hence, the
uppression of protein aggregation by Doxy is unlikely
hrough an effect on Hsp25.
DRC, by itself, is not a common disease, but it exemplifies
ardiac proteinopathies featured by intrasarcoplasmic aberrant
rotein aggregation. Hence, the significance of this study could
e far beyond DRC because preamyloid oligomers were
bserved in the heart tissue of a large subset of human
ongestive heart failure cases resulting from hypertrophic/
ilated cardiomyopathies (4). Moreover, aberrant protein ag-
regates also were observed in pressure-overloaded mouse
cribed in Figure 3 were used. Representative immunoblot images are shown in
ensitometry results from microtubule associated protein light chain 3 (LC3)
r 72 h, starting at 24 h after Ad-HA-CryABR120G infection. Cell lysates were used
yABR120G. Densitometry results from the LC3 immunoblots are summarized in D.
ns as in Figures 1, 4, and 5.s
as des
tg5). D
oxy fo
HA-Cr
eviatioearts (7).
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Doxycycline Ameliorates Desmin-Related Cardiomyopathy October 19, 2010:1418–26Interestingly, although chronic Doxy treatment was shown
o attenuate isoproterenol and transaortic constriction-induced
ardiac hypertrophy (32), Vinet et al. (26) reported that 1
onth, but not 2 months, of low-dose Doxy enhanced
ransaortic constriction-induced hypertrophy. Protective ac-
ions of Doxy on rat diabetic cardiomyopathy also were
eported recently (25).
onclusion
he present study provides compelling pre-clinical evidence
hat Doxy is a promising drug candidate to treat DRC.
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